SIRPA and cancer: Disrupting CD47 to SIRPα is a promising immunotherapeutic strategy for advanced cancers by enhancing ADCP.[31] Therapeutic antibodies can bind to both cancer cells and macrophages, inducing phagocytosis of cancer cells.